Biomaterial Database

Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxydans by DNA restriction fragment length polymorphism. 1994

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

Laboratoire de Bactériologie-Virologie, Hôpital Boucicaut, Paris, France.

We demonstrate that DNA restriction fragment length polymorphism determined by pulsed-field gel electrophoresis is very useful in the investigation of the epidemiology of hospital-acquired infections caused by Alcaligenes denitrificans subsp. xylosoxydans. This approach showed that hospital-acquired infections caused by this opportunistic pathogen over a 6-month period in 10 patients hospitalized in an intensive care unit and a surgical unit were not a true outbreak. In addition, this molecular typing method established that the respiratory therapy equipment was the source of the contamination of two patients.

UI	MeSH Term	Description	Entries
D007362	Intensive Care Units	Hospital units providing continuous surveillance and care to acutely ill patients.	ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009894	Opportunistic Infections	An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D010297	Paris	The capital city of France.
D011014	Pneumonia	Infection of the lung often accompanied by inflammation.	Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D012138	Respiratory Therapy	Care of patients with deficiencies and abnormalities associated with the cardiopulmonary system. It includes the therapeutic use of medical gases and their administrative apparatus, environmental control systems, humidification, aerosols, ventilatory support, bronchopulmonary drainage and exercise, respiratory rehabilitation, assistance with cardiopulmonary resuscitation, and maintenance of natural, artificial, and mechanical airways.	Inhalation Therapy,Therapy, Inhalation,Therapy, Respiratory,Inhalation Therapies,Respiratory Therapies,Therapies, Inhalation,Therapies, Respiratory
D012150	Polymorphism, Restriction Fragment Length	Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment.	RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D003428	Cross Infection	Any infection which a patient contracts in a health-care institution.	Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D004196	Disease Outbreaks	Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS.	Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease

Related Publications

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxidans by DNA restriction fragment length polymorphism.

November 1995, Journal of clinical microbiology,

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

[Thiodiglycol metabolism in Alcaligenes xylosoxydans subsp. denitrificans].

January 2002, Mikrobiologiia,

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

Immunological properties of a penicillinase produced by Alcaligenes denitrificans subsp. xylosoxydans.

September 1987, The Journal of antimicrobial chemotherapy,

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

Investigation of an outbreak due to Alcaligenes xylosoxydans subspecies xylosoxydans by random amplified polymorphic DNA analysis.

February 2002, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

Production of d-Aminoacylase from Alcaligenes denitrificans subsp. xylosoxydans MI-4.

November 1988, Applied and environmental microbiology,

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

Identification of a carbenicillin-hydrolyzing beta-lactamase in Alcaligenes denitrificans subsp. xylosoxydans.

March 1995, Antimicrobial agents and chemotherapy,

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

Peritonitis caused by Alcaligenes denitrificans subsp. xylosoxydans: case report and review of the literature.

November 1986, Journal of clinical microbiology,

M Cheron, and E Abachin, and E Guerot, and M el-Bez, and M Simonet

[Strain Alcaligenes xylosoxydans subsp. Denitrificans TD2 as a biosensor basis for determination of thiodiglycol].

January 2012, Mikrobiologiia,